Chen Chong, Yuan Shiqi, Zhao Xuenuo, Qiao Mengmeng, Li Shuna, He Ningxia, Huang Liying, Lyu Jun
Department of Clinical Research, The First Affiliated Hospital of Jinan University, Guangzhou, China.
School of Public Health, Shannxi University of Chinese Medicine, Xianyang, China.
Front Cardiovasc Med. 2022 Jul 12;9:949113. doi: 10.3389/fcvm.2022.949113. eCollection 2022.
Metformin is the most commonly used drug for patients with diabetes, but there is still some controversy about whether it has a protective effect on cardiovascular health. We therefore used the National Health and Nutritional Examination Survey (NHANES) database to analyze the impact of metformin use on cardiovascular health in patients with diabetes.
We extracted the demographic data and laboratory test results of all people with diabetes in the NHANES database from January 2017 to March 2020. The outcomes were seven indicators of cardiovascular health from the American Heart Association, each was scored as 0, 1, and 2 to represent poor, moderate, and ideal health statuses, respectively. The scores for the indicators (excluding diet and glycemic status) were summed, and the sum score was then considered to indicate unhealthy (0-5) or healthy (>5). Multivariate logistic regression analysis was used, and subgroup analyses were performed by age, alcohol consumption, education, and marital status.
This study included 1,356 patients with diabetes, among which 606 were taking metformin. After adjusting for all included variables, oral metformin in patients with diabetes had a protective effect on the cardiovascular health of patients (OR = 0.724, 95% CI = 0.573-0.913, = 0.007). Subgroup analysis indicated that metformin protects the cardiovascular health of people with diabetes more clearly in those who are young (OR = 0.655, 95% CI = 0.481-0.892, = 0.007), married (OR = 0.633, 95% CI = 0.463-0.863, = 0.003), and drink alcohol (OR = 0.742, 95% CI = 0.581-0.946, = 0.016).
This study found that metformin has a protective effect on the cardiovascular health of patients with diabetes. The study findings support the general applicability of metformin.
二甲双胍是糖尿病患者最常用的药物,但关于其是否对心血管健康具有保护作用仍存在一些争议。因此,我们使用美国国家健康与营养检查调查(NHANES)数据库来分析二甲双胍的使用对糖尿病患者心血管健康的影响。
我们提取了NHANES数据库中2017年1月至2020年3月所有糖尿病患者的人口统计学数据和实验室检查结果。结局指标是美国心脏协会的七项心血管健康指标,每项指标分别记为0、1和2分,分别代表健康状况差、中等和理想。对这些指标(不包括饮食和血糖状况)的得分进行求和,然后将总分视为表明不健康(0 - 5分)或健康(>5分)。采用多因素逻辑回归分析,并按年龄、饮酒情况、教育程度和婚姻状况进行亚组分析。
本研究纳入了1356例糖尿病患者,其中606例正在服用二甲双胍。在对所有纳入变量进行校正后,糖尿病患者口服二甲双胍对患者的心血管健康具有保护作用(OR = 0.724,95%CI = 0.573 - 0.913,P = 0.007)。亚组分析表明,二甲双胍对年轻(OR = 0.655,95%CI = 0.481 - 0.892,P = 0.007)、已婚(OR = 0.633,95%CI = 0.463 - 0.863,P = 0.003)和饮酒(OR = 0.742,95%CI = 0.581 - 0.946,P = 0.016)的糖尿病患者的心血管健康保护作用更明显。
本研究发现二甲双胍对糖尿病患者的心血管健康具有保护作用。研究结果支持二甲双胍的广泛适用性。